Indian stocks: Visit www.stage2stocks.com →

Compass Therapeutics, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Compass Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 23, 2026). It closed at $0.80, 88.0% below its 52-week high and below its 200-day average, which is falling.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. More about the company

$0.80
-3.44% today
$144M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CMPX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 29w
S4 17w
S2 40w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 29w → S1 9w → S4 17w → S1 5w → S2 8w → S3 7w → S2 11w → S3 6w → S4 4w → S1 1w → S2 40w → S3 5w → S4 12w → S1 7w → S4 4w current
Total tracked: 166 weeks across 15 stage runs.

CMPX among Biotechnology469th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…469CMPXStage 4 · wk 511−31.5%
vs 52W High
-88.0%
$0.80 lo$6.69 hi
88.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 5
1w13w26w
Week 5, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-75.9%
200 DMA: $3.33 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.48x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-31.5%
3M
-61.3%
6M
-84.6%
YTD
-84.5%
1Y
-80.4%
Scan Membership
Breakout Watch
Latest: 2025-06-24
5 appearances in last 60 days. First seen: 2022-07-15.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 5 · Vol 0.48x
2026-10-21S4
Wk 5 · Vol 0.29x
2026-10-20S4
Wk 4 · Vol 0.40x
2026-10-19S4
Wk 4 · Vol 0.67x
2026-10-16S4
Wk 4 · Vol 0.43x
2026-10-15S4
Wk 4 · Vol 0.70x
2026-10-14S4
Wk 4 · Vol 1.04x
2026-10-13S4
Wk 3 · Vol 0.80x
2026-10-12S4
Wk 3 · Vol 0.94x
2026-10-09S4
Wk 3 · Vol 0.78x
2026-10-08S4
Wk 3 · Vol 1.53x
2026-10-07S4
Wk 3 · Vol 0.60x
Moving averages & range
50 DMA
$1.65
200 DMA
$3.33
52W High
$6.69
52W Low
$0.80
5D Low
$0.80
Resistance levels (recent highs)
20d High
$1.13
60d High
$2.53
120d High
$2.53
250d High
$6.69
Next resistance
+40.9%
to 20d High
ROE
-56.7%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.9

Compass Therapeutics: quick answers

What stage is Compass Therapeutics in?

As of Oct 22, 2026, Compass Therapeutics (CMPX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 23, 2026 and is in week 5. What the four stages mean

Is Compass Therapeutics in an uptrend?

No. Compass Therapeutics is in a Stage 4 downtrend. It trades 75.9% below its 200-day average, which is falling.

How far is Compass Therapeutics from its 52-week high?

Compass Therapeutics closed at $0.80 on Oct 22, 2026, 88.0% below its 52-week high of $6.69. Its 52-week low is $0.80.

How has Compass Therapeutics performed over the past year?

As of Oct 22, 2026, Compass Therapeutics is down 80.4% over the past year and down 84.5% so far in 2026.

Which sector and industry is Compass Therapeutics in?

Compass Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.